[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hyperlipidemia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hyperlipidemia":30},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,32,0,25,[9,47,88,111,139,162,195,234,253,281,307,334,358,384,415,437,456,478,507,530,561,588,613,639,662],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":21,"enrollmentInfo":22,"targetDuration":4,"studyType":25,"phases":26,"briefSummary":28,"conditions":29,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100568659","ursodeoxycholic-acid-attenuates-statin-induced-impaired-glucose-tolerance-100568659",false,"NCT06684106","Ursodeoxycholic Acid Attenuates Statin-Induced Impaired Glucose Tolerance","Ursodeoxycholic Acid Attenuates Statin-Induced Impaired Glucose Tolerance: A Randomized Controlled Clinical Trial","URSTAR","Inclusion Criteria:\n\n* Age 18-75 years old.\n* LDL-C≥3.4mmol\u002Fl (130 mg\u002FdL).\n* Glycosylated hemoglobin ≤ 6.0% (42 mmol\u002Fmol).\n* Voluntarily sign informed consent.\n\nExclusion Criteria:\n\n* Previous diagnosis of diabetes or prediabetes.\n* Past or current use of hypoglycemic drugs.\n* Oral administration of statin lipid-lowering drugs within three months before enrollment.\n* Combined oral drug quantity ≥3.\n* History of ASCVD (previous myocardial infarction, ACS, stroke or TIA within 1 year, symptomatic peripheral vascular disease).\n* Active liver disease (defined as elevation of alanine aminotransferase (ALT), aspartate aminotransferase (AST) \\>2 × upper limit of normal (ULN) from any existing known liver infectious, neoplastic, or metabolic pathologic cause or unknown cause at the time of screening), Severe hepatic insufficiency and biliary obstruction.\n* Difficult to control hypertension: defined as systolic blood pressure ≥180mmHg or diastolic blood pressure ≥110mmHg despite antihypertensive therapy prior to randomization.\n* Estimated glomerular filtration rate (eGFR) ≤ 30 mL\u002Fmin\u002F1.73m2 using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) method\n* New York Heart Association (NYHA) Class IV heart failure or a known left ventricular ejection fraction \\\u003C 25%\n* A clinically significant and drug- or ablation-resistant arrhythmia within 3 months prior to randomization\n* An acute or severe systemic infection, or any of the following diseases: hematological disorders, autoimmune disorders, malignant tumors, psychiatric patients, or other serious or unstable conditions that could impact study health status\n* Scheduled for surgery within 6 months\n* Pregnant, breastfeeding, or trying to become pregnant during the study or within 6 months of study completion\n* Subjects with alcohol or other drug addiction\n* Secondary hypercholesterolemia, such as hypothyroidism or nephrotic syndrome\n* A history of allergic reaction to any study drug or its excipients or similar chemical classes of drugs\n* A family history of homozygous familial hypercholesterolemia\n* Participants currently enrolled in another clinical trial, or who cannot adhere to 6-month follow-up\n* Any condition that the investigator considers unsuitable for participation.",true,"ALL","18 Years","75 Years",{"count":23,"type":24},128,"ESTIMATED","INTERVENTIONAL",[27],"NA","The purpose of this clinical trial is to understand whether the drug Ursodeoxycholic acid (UDCA) can prevent glucose intolerance in participants with hyperlipidemia who are taking statins. It will also assess the safety of UDCA. The primary questions it aims to answer are:\n\n* Will UDCA reduce the incidence of glucose intolerance in participants taking oral statins?\n* Will the use of UDCA decrease other adverse events in patients taking oral statins?\n\nParticipants will:\n\n* Take Atorvastatin combined with UDCA or a placebo daily for 6 months\n* Have follow-up visits on day 40, day 110, and day 180 Have their examination indicators recorded.",[30,31,32,33],"Hyperlipidemia","Ursodeoxycholic Acid","Statin Therapy","Glucose Intolerance","RECRUITING","2026-06-26",{"date":37,"type":38},"2026-06-30","ACTUAL",{"date":40,"type":38},"2024-11-25",{"date":42,"type":24},"2027-06-01",{"name":44,"class":45},"First Affiliated Hospital Xi'an Jiaotong University","OTHER",2,{"id":48,"slug":49,"hasResults":12,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":54,"targetDuration":56,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":63,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":87},"100644656","management-strategy-of-1l-lorlatinib-with-hyperlipidemia-in-stage-iiib-iv-alk-positive-nsclc-100644656","NCT07674524","Management Strategy of 1L Lorlatinib With Hyperlipidemia in Stage IIIB-IV ALK Positive NSCLC","Management Strategy of 1L Lorlatinib With Hyperlipidemia in Stage IIIB-IV ALK Positive NSCLC: A Multi-center Prospective Study in China","Inclusion Criteria:• Inclusion Criteria (Part A and Part B)\n\nSubjects must meet all of the following inclusion criteria to be eligible for enrollment (Part A and Part B):\n\n1. Diagnosis:\n\n   1. Histologically or cytologically confirmed locally advanced \\[defined as Stage IIIB\u002FC per AJCC v7.0 and not amenable to multimodality treatment\\] or metastatic (Stage IV) ALK-positive NSCLC; ALK status must be confirmed by Ventana ALK (D5F3) Companion Diagnostic (CDx) IHC (Ventana ULTRA or XT platform), FISH, PCR, next-generation sequencing (NGS), or circulating tumor DNA (ctDNA) testing;\n   2. At least one measurable target lesion per RECIST v1.1, not previously irradiated; brain metastases are allowed;\n2. No prior systemic therapy for advanced (Stage IIIB\u002FC not amenable to multimodality treatment) or metastatic (Stage IV) disease;\n3. Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0, 1, or 2;\n4. Age ≥ 18 years;\n5. Hyperlipidemia during first-line lorlatinib treatment, with ULN ≤ TC \\\u003C 12.93 mmol\u002FL (Grade 1-3);\n6. Life expectancy ≥ 6 months;\n7. Negative serum pregnancy test at screening for women of childbearing potential. Non-childbearing potential must meet at least one of the following:\n\n   1. Postmenopausal status: regular menstrual cessation ≥ 12 months with no other pathological or physiological cause (serum FSH level may be used to confirm postmenopausal status, if applicable);\n   2. Hysterectomy and\u002For bilateral oophorectomy;\n   3. Medically confirmed ovarian failure; All other women (including those with tubal ligation) are considered of childbearing potential;\n8. Provide signed and dated informed consent from the patient (or legal representative), indicating full understanding of the study-related information.\n\nPart B Additional Inclusion Criteria\n\nPatients with at least one prior major ASCVD event, or baseline LDL-C ≥ 4.9 mmol\u002FL ± high-risk factors.\n\nMajor ASCVD events:\n\n1. Acute coronary syndrome (ACS) within the past 1 year;\n2. History of myocardial infarction (excluding recent ACS);\n3. History of ischemic stroke;\n4. Symptomatic peripheral artery disease (PAD), including prior revascularization or amputation.\n\nHigh-risk factors (prioritized):\n\n1. Premature coronary artery disease (male \\\u003C 55 years; female \\\u003C 65 years);\n2. Familial hypercholesterolemia;\n3. History of coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI);\n4. Diabetes mellitus;\n5. Hypertension;\n6. Chronic kidney disease (CKD) stage 3-4;\n7. Current smoker. -\n\nExclusion Criteria:\n\nExclusion Criteria (Part A and Part B)\n\n1. Mixed squamous cell carcinoma, large cell carcinoma, or small cell lung cancer\n2. Prior systemic anticancer therapy for NSCLC, including chemotherapy, biologic therapy, immunotherapy, or any investigational drug\n3. Diagnosed genetic hypercholesterolemia (e.g., familial hypercholesterolemia, Part A only) or secondary dyslipidemia with a clear etiology (e.g., hypothyroidism, uncontrolled diabetes, nephrotic syndrome)\n4. Known allergy or history of severe adverse reaction to any study drug (including lorlatinib, statins, ezetimibe, or evolocumab)\n5. Presence of other severe diseases that may affect study compliance or outcome assessment, including advanced renal failure (eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m²) or severe hepatic impairment (Child-Pugh Class C)\n6. Pregnant or lactating women, or fertile individuals (male or female) unwilling to use effective contraception during the study\n7. Currently participating in another interventional clinical study that may interfere with this study; patients expected to be unable to complete follow-up or the first tumor efficacy assessment; patients with mental or psychological disorders who cannot provide informed consent or comply with study requirements (including treatment and follow-up)\n\nPart B Additional Exclusion Criteria\n\nSubjects meeting any of the following criteria will not be included in this clinical study:\n\n1. Major surgery within 4 weeks prior to randomization; minor surgery (e.g., port placement) is permitted provided the incision is adequately healed\n2. Radiotherapy within 2 weeks prior to enrollment, including stereotactic or partial brain radiotherapy. Patients who complete whole brain radiotherapy within 4 weeks prior to randomization, or palliative radiotherapy outside the CNS within 48 hours prior to randomization, are also excluded\n3. Gastrointestinal abnormalities including: inability to take oral medication; need for parenteral nutrition; prior surgery affecting absorption (e.g., total gastrectomy, gastric banding); active inflammatory bowel disease, chronic diarrhea, symptomatic diverticular disease; treatment for active peptic ulcer within the past 6 months; malabsorption syndrome\n4. Known or suspected severe hypersensitivity to the study drug or any of its excipients\n5. History of extensive, disseminated, or bilateral disease, or current Grade 3-4 interstitial fibrosis\u002Finterstitial lung disease, including but not limited to: pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, interstitial lung disease, bronchiolitis obliterans, and pulmonary fibrosis\n6. Active malignancy within 3 years prior to randomization (excluding NSCLC, non-melanoma skin cancer, localized prostate cancer not requiring immediate treatment, or any carcinoma in situ)\n7. Concurrent use within 12 days prior to first lorlatinib dose of:\n\n   1. Strong CYP3A inhibitors (e.g., grapefruit juice or grapefruit\u002Frelated citrus fruits \\[Seville oranges, pomelos\\]; boceprevir, cobicistat, conivaptan, itraconazole, ketoconazole, posaconazole; ritonavir alone or with danoprevir, elvitegravir, indinavir, lopinavir, paritaprevir, ombitasvir, dasabuvir, saquinavir, tipranavir; telaprevir, troleandomycin, voriconazole. Topical use such as 2% ketoconazole cream is permitted where applicable)\n   2. Known narrow therapeutic index CYP3A substrates (e.g., astemizole, terfenadine, cisapride, pimozide, quinidine, tacrolimus, cyclosporine, sirolimus, alfentanil, fentanyl \\[including transdermal patch\\], or ergot alkaloids \\[ergotamine, dihydroergotamine\\]) (withdrawn from U.S. market)\n   3. Known strong CYP3A inducers (e.g., carbamazepine, enzalutamide, mitotane, phenytoin, rifampin, St. John's Wort)\n   4. Known narrow therapeutic index P-gp substrates (e.g., digoxin)\n8. Other severe acute or chronic medical or psychiatric conditions, including suicidal ideation or behavior within the past 1 year, that may increase the risk of study participation or study drug use, or laboratory abnormalities that may interfere with interpretation of study results, and patients deemed by the investigator to be unsuitable for enrollment\n9. Participation in another investigational drug study within 2 weeks prior to enrollment and\u002For during the study period",{"count":55,"type":24},160,"24 Years","OBSERVATIONAL","For Patients and Families\n\nBrief Title: Management of 1L Lorlatinib with Hyperlipidemia in ALK+ Advanced NSCLC\n\nWhat is this study about?\n\nThis study is for people with ALK-positive non-small cell lung cancer (NSCLC) who are taking lorlatinib (Lorbrena®) as their first treatment and have developed high cholesterol (hyperlipidemia) as a side effect.\n\nWhy is this study needed?\n\nLorlatinib is a highly effective targeted therapy, but it frequently causes elevated cholesterol and triglycerides. There is currently no standard guideline on how to best manage this side effect. This study aims to find the best approach to control lipid levels while on lorlatinib treatment.\n\nWhat will happen in this study?\n\nThe study has two parts:\n\n* Part A (Observational) : About 100 participants. Doctors manage hyperlipidemia according to routine clinical practice. Researchers simply observe and record which lipid-lowering treatments are used and how well they work.\n* Part B (Randomized Controlled Trial) : 60 participants with high-risk factors are randomly assigned to either:\n* Intensive treatment: rosuvastatin + ezetimibe + evolocumab\n* Standard treatment: rosuvastatin + ezetimibe\n\nWhat tests are involved?\n\n* Blood tests for lipid levels at baseline, Weeks 4, 8, 20, and 24\n* Routine CT or MRI scans for tumor assessment\n* Some participants in Part B may have a non-invasive vascular ultrasound (FMD) test\n* Total participation per patient: up to 7 months\n\nIs this study safe?\n\n* ✅ Approved by the Ethics Committee of Sun Yat-sen University Cancer Center\n* ✅ All drugs used (lorlatinib, statins, ezetimibe, evolocumab) are already approved and widely used\n* ✅ An independent Data Monitoring Committee (DMC) monitors safety throughout the study\n* ✅ Participants may withdraw at any time without affecting their regular care\n\nFor Healthcare Providers\n\nStudy Title: Management strategy of 1L Lorlatinib with Hyperlipidemia in Stage IIIB-IV ALK positive NSCLC: A multi-center prospective study in China\n\nSponsor \u002F Investigators: Sun Yat-sen University Cancer Center (PI: Prof. Zhang Li)\n\nStudy Type:\n\n* Part A: Observational, prospective, real-world cohort study\n* Part B: Prospective, randomized controlled trial (RCT)\n\nEstimated Enrollment: 160 participants (Part A: \\~100, Part B: 60)\n\nStudy Duration: Approximately 4 years (anticipated completion: December 2029)\n\nKey Inclusion Criteria:\n\n* Stage IIIB-IV ALK+ NSCLC (confirmed by IHC, FISH, PCR, NGS, or ctDNA)\n* No prior systemic therapy for advanced\u002Fmetastatic disease\n* ECOG PS 0-2\n* Age ≥ 18 years\n* Hyperlipidemia (ULN ≤ TC \\\u003C 12.93 mmol\u002FL, Grade 1-3) while on first-line lorlatinib\n* At least one measurable lesion per RECIST v1.1\n* Life expectancy ≥ 6 months\n\nPrimary Endpoints:\n\n* Part A: Describe real-world treatment patterns for hyperlipidemia management\n* Part B: Percentage change in LDL-C from baseline to Week 12\n\nOversight:\n\n* Independent Data Monitoring Committee (DMC)\n* Trial Management Committee\n* Ethics Committee of Sun Yat-sen University Cancer Center (Approval No. B2026-159-01)\n\nParticipating Centers: 8 sites across China",[60,30,61,62],"Non-Small Cell Lung Cancer (NSCLC)","ALK Gene Mutation","ALK-positive",[64,65,30,66,67,68,69,70,71,72,73,74,75,76],"Lorlatinib","ALK-positive NSCLC","Lipid management","Statin","Ezetimibe","Evolocumab","PCSK9 inhibitor","Real-world study","Randomized controlled trial","Prospective study","Endothelial function","FMD","Multi-center","NOT_YET_RECRUITING","2026-06-24",{"date":80,"type":38},"2026-06-29",{"date":82,"type":24},"2026-08-01",{"date":84,"type":24},"2029-12-31",{"name":86,"class":45},"Sun Yat-sen University",1,{"id":89,"slug":90,"hasResults":12,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":4,"eligibilityCriteria":94,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":95,"enrollmentInfo":96,"targetDuration":4,"studyType":25,"phases":98,"briefSummary":99,"conditions":100,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":87},"100644389","assessment-of-the-effects-and-safety-of-spermidine-supplementation-on-blood-lipids-and-body-weight-in-overweight-or-obese-individuals-with-hyperlipidemia-100644389","NCT07662330","Assessment of the Effects and Safety of Spermidine Supplementation on Blood Lipids and Body Weight in Overweight or Obese Individuals With Hyperlipidemia","Assessment of the Effects and Safety of Spermidine Supplementation on Blood Lipids and Body Weight in Overweight or Obese Individuals With Hyperlipidemia: A Randomized, Double-Blind, Placebo-Controlled Trial","Inclusion Criteria:\n\n* Males or females aged 18 to 65 years.\n* BMI ≥ 24 kg\u002Fm², without severe chronic diseases.\n* Not currently using glucose-lowering or lipid-lowering medications.\n* Dyslipidemia defined as triglycerides ≥ 1.7 mmol\u002FL or total cholesterol ≥ 5.2 mmol\u002FL.\n* No active weight loss or weight gain diet within the past 1 month.\n* No special dietary pattern changes (e.g., ketogenic, vegan, high-protein, meal replacement, intermittent fasting) within the past 1 month.\n* No use of supplements that may affect polyamine intake (e.g., germ, yeast, fermented extracts, nutritional powders) within the past 2-4 weeks.\n* Willing and able to provide signed informed consent.\n\nExclusion Criteria:\n\n* Diagnosis of acute or severe gastrointestinal disease\n* Concurrent participation in any other weight-loss therapy\n* Current use of hypoglycemic or lipid-lowering medications\n* Participation in any other clinical trial within one month prior to signing the informed consent form\n* Pregnancy, lactation, or planning a pregnancy during the trial period\n* Known allergy to cellulose or wheat\n* History of cancer\n* Renal insufficiency, indicated by abnormal serum creatinine levels\n* Hepatic impairment, defined as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\>3 × upper limit of normal (ULN), or total bilirubin (TBIL) \\>3 × ULN\n* Any other condition deemed by the investigator as inappropriate for trial participation","60 Years",{"count":97,"type":24},50,[27],"Evaluate the effect of spermidine supplementation on lipid profile changes in individuals with overweight or obesity accompanied by hyperlipidemia. Analyze the impact of spermidine on metabolic parameters and assess the safety of spermidine supplementation, including liver and kidney function, gastrointestinal reactions, and other adverse effects.",[101,30],"Obesity & Overweight","2026-06-22",{"date":104,"type":38},"2026-06-23",{"date":106,"type":38},"2026-01-01",{"date":108,"type":24},"2027-01-31",{"name":110,"class":45},"Shanghai 10th People's Hospital",{"id":112,"slug":113,"hasResults":12,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":4,"eligibilityCriteria":117,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":118,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":120,"conditions":121,"keywords":125,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":135,"leadSponsor":137,"locationsCount":87},"100640569","regional-innovation-in-chronic-disease-and-elderly-care-100640569","NCT07578090","Regional Innovation in Chronic Disease and Elderly Care","A Regional Integrated Care Innovation Program for Cardiometabolic Health, Pulmonary-Circulatory Disease Management, and Elderly Support","Inclusion Criteria:\n\n* Participants with hypertension, hyperglycemia, or hyperlipidemia who meet at least one of these criteria are eligible for enrollment.\n\nExclusion Criteria:\n\n* Age under 18 years\n* Patients diagnosed with neuromuscular disorders\n* Inability to perform cardiopulmonary exercise testing\n* Refusal to participate in the study",{"count":119,"type":24},1000,"This project aims to develop a community-based health promotion intervention model for populations at potential risk of metabolic syndrome. Through exercise training and lifestyle modifications, the project seeks to improve cardiopulmonary function and disease control, align with current public health policies, and establish an evidence-based model with strong potential for broader implementation.",[122,123,30,124],"Hypertension","Cardiovascular Disease","Hyperglycemia",[126,127,128,129,130],"hypertension","exercise training","cardiovascular disease","hyperlipidemia","hyperglycemia","2026-05-26",{"date":133,"type":38},"2026-05-28",{"date":131,"type":38},{"date":136,"type":24},"2026-12-31",{"name":138,"class":45},"Fu Jen Catholic University",{"id":140,"slug":141,"hasResults":12,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":4,"eligibilityCriteria":145,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":146,"targetDuration":4,"studyType":25,"phases":148,"briefSummary":150,"conditions":151,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":87},"100610680","phase-3-a-trial-to-evaluate-the-efficacy-and-safety-of-shr-1918-in-patients-with-hyperlipidemia-100610680","NCT07230730","A Trial to Evaluate the Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemia","A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemia","Inclusion Criteria:\n\n1. the age must be at least 18 years old, and both men and women are eligible;\n2. the patient was receiving a stable dose of statins at the time of screening,, and the fasting LDL-C met: For individuals with extremely high risk of ASCVD, LDL-C≥1.4 mmol\u002FL; for those with very high risk of ASCVD, LDL-C≥1.8 mmol\u002FL; and for those with medium and high risk of ASCVD, ≥2.6 mol\u002FL;\n3. Fasting TG≥ 1.7 mmol\u002FL;\n4. Understand the research procedures and methods, voluntarily participate in this trial and sign the informed consent form in person；\n\nExclusion Criteria:\n\n1. poorly controlled hypertension (systolic blood pressure ≥160 mmHg and\u002For diastolic blood pressure ≥100 mmHg) at the time of screening or before randomization；\n2. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) or γ -glutamyl transferase (GGT) \\> 3× upper limit of normal (ULN), or total bilirubin \\> 2×ULN；\n3. Thyroid stimulating hormone (TSH) is lower than the lower limit of normal (LLN) or greater than 1.5×ULN；\n4. The estimated glomerular filtration rate (eGFR) is less than 30 mL\u002Fmin\u002F1.73m2；\n5. Previously suffering from diseases that have a significant impact on blood lipid levels, such as nephrotic syndrome, severe liver diseases, Cushing's syndrome, etc",{"count":147,"type":24},900,[149],"PHASE3","The study is being conducted to evaluate the efficacy, and safety of SHR-1918 in reducing serum low-density lipoprotein cholesterol (LDL-C) and total triglycerides (TG) in patients with hyperlipidemia compared with placebo, and also includes To evaluate the effectiveness of SHR-1918 in reducing other lipid indicators in patients with mixed hyperlipidemia and to assess the safety of SHR-1918 in patients with mixed hyperlipidemia.",[30],"2026-05-12",{"date":154,"type":38},"2026-05-14",{"date":156,"type":38},"2026-01-13",{"date":158,"type":24},"2027-10",{"name":160,"class":161},"Beijing Suncadia Pharmaceuticals Co., Ltd","INDUSTRY",{"id":163,"slug":164,"hasResults":12,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":168,"eligibilityCriteria":169,"healthyVolunteers":12,"sex":19,"minAge":4,"maxAge":4,"enrollmentInfo":170,"targetDuration":4,"studyType":25,"phases":172,"briefSummary":173,"conditions":174,"keywords":181,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":87},"100639290","new-taipei-city-888-digital-medical-ai-platform-for-prevention-and-care-of-the-three-highs-and-cardio-renal-vascular-diseases-100639290","NCT07588256","New Taipei City 888 Digital Medical AI Platform for Prevention and Care of the Three Highs and Cardio-Renal-Vascular Diseases","New Taipei City 888 Digital Medical AI Platform for the Prevention and Treatment of the Three Highs (Hypertension, Hyperglycemia, Hyperlipidemia) and Cardio-Renal-Vascular Diseases: Validation and Implementation Through Large-Scale Cluster Randomized Clinical Trials: T-888-DIGICARE-DREAM","DIGICARE-DREAM","Inclusion Criteria:\n\nI.T-888-DIGICARE：\n\nEligible participants must meet the definition of hypertension and at least one of the following chronic (non-hypertensive) conditions:\n\n1. Hypertension\n\n   * With or without treatment, and meeting one of the following:\n   * Office blood pressure: two consecutive measurements \\>130\u002F80 mmHg\n   * Home blood pressure: weekly average (morning\u002Fevening) \\>130\u002F80 mmHg, or more than half of the weekly measurements exceeding this threshold\n2. Hyperlipidemia\n\n   * With or without treatment, and\n   * LDL-C \\>100 mg\u002FdL (or \\>70 mg\u002FdL in patients with diabetes or established ASCVD)\n3. Diabetes Mellitus\n\n   * With or without treatment, and\n   * HbA1c \\>6.5%\n4. Chronic Kidney Disease (CKD)\n\n   * Estimated glomerular filtration rate (eGFR) \\\u003C60 mL\u002Fmin\u002F1.73 m², and\n   * Urine albumin-to-creatinine ratio (UACR) \\>30 mg\u002Fg\n5. Atherosclerotic Cardiovascular Disease (ASCVD):\n\n   * Including coronary artery disease, cerebrovascular disease, peripheral arterial disease, or aortic pathology\n\nII. DREAM-G:\n\n1. Hypertension\n\n   * With or without treatment, and meeting one of the following:\n   * Office blood pressure: two consecutive measurements \\>130\u002F80 mmHg\n   * Home blood pressure: weekly average (morning\u002Fevening) \\>130\u002F80 mmHg, or more than half of weekly measurements exceeding this threshold\n2. Hyperlipidemia\n\n   * With or without treatment, and\n   * LDL-C \\>100 mg\u002FdL (or \\>70 mg\u002FdL in patients with diabetes or established ASCVD)\n3. Diabetes Mellitus\n\n   * With or without treatment, and\n   * HbA1c \\>6.5%\n4. Chronic Kidney Disease (CKD)\n\n   * Estimated glomerular filtration rate (eGFR) \\\u003C60 mL\u002Fmin\u002F1.73 m², and\n   * Measurable urinary microalbumin-to-creatinine ratio\n5. Atherosclerotic Cardiovascular Disease (ASCVD):\n\n   • Including coronary artery disease, cerebrovascular disease, peripheral arterial disease, or aortic pathology\n\n   Participants must meet at least one of the above chronic disease conditions and:\n6. Untreated Hypertension:\n\n   * Morning home blood pressure (HBP) \\>130\u002F80 mmHg: weekly average (≥4 days) \\>130\u002F80 mmHg,\n   * Or more than half of morning HBP measurements (≥4 days per week) \\>130\u002F80 mmHg\n7. Treated Hypertension:\n\n   * Morning home blood pressure \\>130\u002F80 mmHg: weekly average (≥4 days) \\>130\u002F80 mmHg,\n   * Or more than half of morning HBP measurements (≥4 days per week) \\>130\u002F80 mmHg\n   * Average home blood pressure ≤130\u002F80 mmHg (used to determine treatment strategy)\n\nExclusion Criteria:\n\nI. T-888-DIGICARE\n\n1. Symptomatic heart failure (New York Heart Association functional class II-IV)\n2. End-stage renal disease requiring long-term dialysis\n3. Pregnant women or those planning pregnancy\n\nII. DREAM-G:\n\n1. Life expectancy \\\u003C1 year\n2. End-stage renal disease (ESRD) requiring regular renal replacement therapy, including dialysis, kidney transplantation, or palliative care\n3. Severe liver cirrhosis\n4. Malignancy under active treatment",{"count":171,"type":24},4162,[27],"Non-communicable diseases (NCDs), or chronic diseases, are a major public health burden globally and in Taiwan, and control of the \"three highs\" (hypertension, dyslipidemia, and hyperglycemia) is a national priority. Nearly half of the 10 leading causes of death in Taiwan are directly or indirectly related to atherosclerotic cardiovascular disease (ASCVD), for which hypertension, dyslipidemia, and abnormal blood glucose are the major risk factors. National health insurance data indicate that over 70% of middle-aged and older adults have at least one of these chronic conditions. Early stages are often asymptomatic, and inadequate control may lead to complications of cardiovascular disease, stroke, renal vascular disease, and retinopathy, causing irreversible organ damage and death.\n\nFor blood pressure, large clinical trials such as SPRINT and STEP have shown that targeting systolic blood pressure below 130 mmHg significantly reduces ASCVD events. For LDL cholesterol, \"the lower, the better\" applies, with guideline-recommended LDL-C targets determined by baseline ASCVD risk, with levels below 55 mg\u002FdL for very high-risk patients. For diabetes, treatment goals generally include fasting plasma glucose below 130 mg\u002FdL and glycated hemoglobin (HbA1c) below 7%.\n\nAlthough antihypertensive therapy has been proven effective in preventing cardiovascular disease and chronic kidney disease attributable to hypertension, fewer than one-third of patients receiving antihypertensive medications achieve current guideline-recommended blood pressure targets. No randomized clinical trial to date has used home blood pressure as the primary therapeutic reference. Moreover, long-term evidence is lacking regarding the organ-protective effects of strategies targeting morning hypertension and of bedtime dosing regimens. Although the TIME study is currently the largest and longest-followed trial addressing dosing time, its bedtime-dosing arm was not specifically targeted to patients with morning hypertension. Therefore, we propose a clinical trial to investigate management strategies for morning hypertension. Aligned with the 2022 Taiwan Hypertension Guidelines, we will employ the \"722 protocol\" for home blood pressure monitoring and enroll patients with morning home blood pressure ≥130\u002F80 mmHg to compare selective nocturnal administration of antihypertensive agents versus exclusive morning dosing, assessing differences in morning home blood pressure control rates, end-organ damage, and atherosclerotic cardiovascular disease (ASCVD) events.\n\nThis project will implement two large-scale cluster-randomized clinical trials within the New Taipei City healthcare network. The first trial (T-888-DIGICARE) will evaluate whether a mobile digital health platform augmented with interactive digital modules can more effectively achieve the \"888\" targets for prevention and treatment of the Three Highs (Hypertension, Hyperglycemia, Hyperlipidemia). The second trial (DREAM-G) will use the same mobile health delivery model to investigate whether the timing of antihypertensive medication administration (nocturnal versus morning dosing) differentially affects patients with poor morning home blood pressure control. Beyond generating rigorous evidence through a novel clinical approach, this program is expected to have substantial global clinical impact and to showcase Taiwan's healthcare capabilities internationally. Operational challenges encountered and solutions developed during the trials will also provide critical feasibility data for the concurrent real-world implementation registry (T-888-DIGICARE-Registry). The registry will run in parallel with the cluster trials and will enroll individuals who decline trial participation at baseline as well as participants after trial completion, thereby serving as a continuity and real-world evidence platform.",[175,176,177,178,179,122,180,30],"Microalbuminuria","Microalbuminuria \u002FCreatinine Ratios ACR","Cardiovascular Disease Risk Factor","Cardiovascular Disease Prevention","Digital Medicine","Hyperglycaemia (Diabetic)",[182,126,183,184,185,186],"digital medicine","home blood pressure monitoring","dyslipidemia","microalbuminuria","diabetes","2026-05-11",{"date":154,"type":38},{"date":190,"type":38},"2026-02-05",{"date":192,"type":24},"2029-02-05",{"name":194,"class":45},"New Taipei City Medical Association",{"id":196,"slug":197,"hasResults":12,"nctId":198,"briefTitle":199,"officialTitle":199,"acronym":200,"eligibilityCriteria":201,"healthyVolunteers":12,"sex":19,"minAge":202,"maxAge":21,"enrollmentInfo":203,"targetDuration":4,"studyType":25,"phases":205,"briefSummary":206,"conditions":207,"keywords":216,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":87},"100562453","changes-in-plaque-characteristics-after-short-term-statin-therapy-as-assessed-with-coronary-ct-100562453","NCT06603363","Changes in Plaque Characteristics After Short-term Statin Therapy as Assessed With Coronary CT","INTENSE","Inclusion Criteria:\n\n* patients referred for coronary computed tomography angiography (CTA)\n* females aged 45-75 years and males aged 40-75 years\n* presence of at least mild coronary atherosclerosis (luminal stenosis \\>25%, with at least one partially calcified or non-calcified plaque)\n* statin-naive patients\n* ability to understand and provide written informed consent\n* FFR-CT value ≥0.75, indicating the absence of hemodynamically significant stenosis\n\nExclusion Criteria:\n\n* contraindications to coronary CTA\n* current or prior treatment with statins or other lipid-lowering agents (e.g., ezetimibe)\n* age below 45 years in females or below 40 years in males\n* age above 75 years in both sexes\n* pregnancy or breastfeeding\n* type 1 or type 2 diabetes mellitus\n* history of coronary stent implantation or coronary artery bypass grafting\n* history of myocardial infarction\n* ≥70% luminal stenosis in the proximal left anterior descending artery (LAD), or ≥50% stenosis in the left main (LM) coronary artery\n* FFR-CT value \\\u003C0.75 in any coronary artery\n* elevated serum alanine aminotransferase (ALT) levels (\\>3× the upper limit of normal)\n* elevated serum creatine kinase (CK) levels (\\>3× the upper limit of normal)\n* LDL cholesterol level \\>5 mmol\u002FL\n* renal failure or significantly impaired renal function (eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m²)\n* ongoing oncological treatment\n* active liver disease\n* known hypersensitivity to any excipients of the investigational product\n* concomitant treatment with the combination of sofosbuvir\u002Fvelpatasvir\u002Fvoxilaprevir\n* concomitant treatment with cyclosporine\n* women of childbearing potential not using adequate contraception\n* presence of myopathy","45 Years",{"count":204,"type":24},140,[27],"INTENSE Trial is a prospective, double-blind, randomized, placebo-controlled, single-center study with two arms (40 mg intensified statin therapy vs matching placebo for rosuvastatin) among statin-naive patients referred to coronary CT angiography due to stable chest pain, followed for 24 months by using a photon-counting detector CT (PCD-CT).\n\nINTENSE Trial aims 1) to assess the effect of short-term intensified statin therapy on coronary anatomy and physiology using PCD-CT and 2) to determine the impact of short-term, intensified statin therapy on coronary plaque morphology and hemodynamics to identify statin responder and non-responder patients in addition to testing the hypothesis of \"plaque memory\" after the 24-month follow-up period.",[208,209,210,32,211,212,213,214,215,30],"Coronary Artery Disease","Atherosclerotic Plaque","Coronary Computed Tomography Angiography","Multidetector Computed Tomography","Heart Diseases","Cardiovascular Diseases","Arteriosclerosis","Vascular Diseases",[217,218,219,220,221,222,223,224],"coronary artery disease","stable chest pain","intermediate pretest probability","explanatory randomised controlled trial","coronary computed tomography angiography","photon-counting detector CT","atherosclerotic plaque","statin therapy","2026-05-08",{"date":227,"type":38},"2026-05-13",{"date":229,"type":38},"2025-05-28",{"date":231,"type":24},"2028-12-15",{"name":233,"class":45},"Prof. Maurovich-Horvat Pál",{"id":235,"slug":236,"hasResults":12,"nctId":237,"briefTitle":238,"officialTitle":238,"acronym":4,"eligibilityCriteria":239,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":240,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":242,"conditions":243,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":245,"startDateStruct":247,"completionDateStruct":249,"leadSponsor":251,"locationsCount":4},"100634936","development-and-clinical-validation-of-key-technologies-for-non-invasive-breath-metabolic-fingerprinting-for-large-scale-population-lipid-screening-100634936","NCT07546162","Development and Clinical Validation of Key Technologies for Non-invasive Breath Metabolic Fingerprinting for Large-scale Population Lipid Screening","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Voluntarily sign the informed consent form\n\nExclusion Criteria:\n\n1. Patients with lung cancer, asthma, chronic obstructive pulmonary disease, cystic fibrosis, or acute respiratory distress syndrome\n2. Women during pregnancy or breastfeeding\n3. Patients with chronic kidney disease (GFR \\\u003C60 ml\u002Fmin) or liver cirrhosis\n4. Individuals unable to cooperate in collecting exhaled breath samples",{"count":241,"type":24},280,"This study collects exhaled breath condensate samples from healthy populations and hyperlipidemic populations, analyzes the characteristics of the exhaled metabolic lipid profile for early identification of people with abnormal blood lipids, verifies the feasibility and accuracy of a new gas detection method for screening abnormal blood lipids, and explores a simple, fast, and non-invasive method for screening abnormal blood lipids.",[30],"2026-04-20",{"date":246,"type":38},"2026-04-22",{"date":248,"type":24},"2026-04-02",{"date":250,"type":24},"2026-05-31",{"name":252,"class":45},"Beijing Anzhen Hospital",{"id":254,"slug":255,"hasResults":12,"nctId":256,"briefTitle":257,"officialTitle":258,"acronym":4,"eligibilityCriteria":259,"healthyVolunteers":18,"sex":19,"minAge":260,"maxAge":4,"enrollmentInfo":261,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":263,"conditions":264,"keywords":268,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":273,"startDateStruct":275,"completionDateStruct":277,"leadSponsor":279,"locationsCount":46},"100630965","chronic-kidney-disease-and-metabolic-disorders-in-the-elderly-100630965","NCT07494526","Chronic Kidney Disease and Metabolic Disorders in the Elderly","Research on the Prevention, Control, and Intelligent Management Decision-Making for Comorbidities of Chronic Kidney Disease and Metabolic Disorders in the Elderly","For Sub-cohort 1, the inclusion and exclusion criteria are as follows:\n\nInclusion Criteria:\n\n1. Baseline age ≥ 65 years.\n2. Availability of baseline data on serum creatinine and at least one urinary protein measurement.\n3. Urinary protein measurements include: UACR, UPCR, 24-hour urine protein quantification, and urine protein dipstick test.\n4. Baseline date requirement: Between January 1, 2010, and December 31, 2025.\n5. Follow-up requirement meeting at least one of the following: At least one serum creatinine measurement with an interval of ≥ 6 months after baseline. Occurrence of a primary endpoint event (new-onset CKD).\n\nExclusion Criteria:\n\nPresence of CKD at baseline, defined as: Glomerular filtration rate (eGFR) \\\u003C 60 ml\u002F(min·1.73m²) or positive urine protein; or the presence of an ICD-10 diagnostic code for CKD in medical records.\n\nFor Sub-cohort 2 (CKD Patients), the inclusion and exclusion criteria are as follows:\n\nInclusion Criteria:\n\n1. Baseline age ≥ 65 years.\n2. Meeting the diagnostic criteria for CKD: Glomerular filtration rate (eGFR) \\\u003C 60 ml\u002F(min·1.73m²) or urine protein (UACR ≥ 30 mg\u002Fg); or based on ICD-10 codes.\n3. Baseline date requirement: Between January 1, 2010, and December 31, 2025.\n4. Follow-up requirement meeting at least one of the following:\n\nOccurrence of a primary endpoint event (mortality, ESRD); At least one serum creatinine measurement with an interval of ≥ 6 months after baseline.\n\nExclusion Criteria:\n\n1. End-stage renal disease (ESRD) at baseline (eGFR \\\u003C 15 ml\u002F(min·1.73m²), or prior receipt of kidney transplant or dialysis), based on ICD codes).\n2. Diagnosis of acute kidney injury (AKI) within the preceding 3 months.\n3. New York Heart Association (NYHA) Class III or IV heart failure or occurrence of acute myocardial infarction within the preceding 6 months.\n4. Child-Pugh Class B or C liver cirrhosis.\n5. Malignant neoplasm.","65 Years",{"count":262,"type":24},100000,"The goal of this observational study is to investigate the impact of metabolic comorbidities on outcomes in elderly Chinese adults, through two parallel sub-cohorts: one comprising elderly individuals without chronic kidney disease (CKD) at baseline, and one comprising elderly patients with established CKD.\n\nThe main questions it aims to answer are:\n\nDo metabolic diseases (diabetes, hypertension, hyperlipidemia, hyperuricemia, calcium-phosphorus disorders) increase the risk of incident CKD, major adverse cardiovascular events (MACE), and all-cause mortality in elderly individuals without CKD at baseline? What are the optimal diagnostic thresholds and criteria for CKD in the elderly population? How do metabolic comorbidities affect long-term outcomes - including all-cause mortality, end-stage renal disease (ESRD), and cardiovascular events - in elderly patients with established CKD? What is the comorbidity profile and disease burden of elderly CKD patients in China?\n\nParticipants in both sub-cohorts will:\n\nUndergo baseline assessments including laboratory tests and clinical evaluations.\n\nProvide longitudinal follow-up data through scheduled clinic visits and medical record linkage.\n\nContribute to a large-scale cohort of 100,000 elderly participants across multiple centers in China.",[265,266,122,30,267],"Chronic Kidney Diease","Diabetes Mellitus","Hyperuricemia",[269,270,271],"chronic kidney disease","elderly","metabolic disorders","2026-03-20",{"date":274,"type":38},"2026-03-27",{"date":276,"type":24},"2026-04",{"date":278,"type":24},"2028-12",{"name":280,"class":45},"Chinese PLA General Hospital",{"id":282,"slug":283,"hasResults":12,"nctId":284,"briefTitle":285,"officialTitle":286,"acronym":287,"eligibilityCriteria":288,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":289,"targetDuration":4,"studyType":25,"phases":291,"briefSummary":292,"conditions":293,"keywords":295,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":299,"startDateStruct":301,"completionDateStruct":303,"leadSponsor":305,"locationsCount":87},"100601991","duke-cardiometabolic-prevention-clinics-impact-on-high-risk-cardiovascular-patients-with-uncontrolled-risk-factors-100601991","NCT07117695","Duke Cardiometabolic Prevention Clinic's Impact on High-risk Cardiovascular Patients With Uncontrolled Risk Factors","Efficacy of Multidisciplinary Prevention Clinic Model for Cardiovascular Risk Reduction in High Risk Patients","DUKE PREVENT","Inclusion Criteria:\n\n1. Adults ≥ 18 years of age\n2. Prior history of cardiovascular disease (prior history of CAD, MI, ischemic stroke, PVD, any arterial revascularization)\n3. Type 2 Diabetes\n4. Uncontrolled sBP AND LDL-C within the preceding 3 months:\n\n   * SBP \\> 150mmHg on at least 1 occasion in last 3 months, AND\n   * LDL \\> 130mg\u002FdL in last 3 months\n\n     * NOTE: If there are not enough patients with the above inclusion criteria available for enrollment, then we will expand the criteria to include patients with uncontrolled sBP and LDL-C within the last 6 months.\n\nExclusion Criteria:\n\n1. Currently or previously established with providers in the Duke Cardiometabolic Prevention Clinic (Pagidipati, Shah, McGarrah, Blazing, Kelsey)\n2. History of advanced dementia\n3. Referred to hospice\u002Fon hospice\n4. Lives outside of Durham County, Orange County, Wake County, Person County or Granville County\n5. End Stage Renal Disease (those on dialysis or with EGFR \\\u003C20)\n6. History of cardiac transplant\u002FListed for Cardiac Transplant\u002FFollowed by Advanced Heart Failure\n7. Pregnant\u002FPlanning to become pregnant during study period",{"count":290,"type":24},150,[27],"This project is studying whether a team-based specialty clinic can help people with type 2 diabetes and heart disease better manage their blood pressure and cholesterol. The clinic includes coordinated care from heart doctors, kidney doctors, diabetes specialists, and liver doctors.\n\nThe study will compare two groups of patients: one receiving usual care from their primary care provider, and one referred to the Duke Cardiometabolic Prevention Clinic for multidisciplinary care. The main goals are to find out if this clinic improves blood pressure and cholesterol control over 12 months, increases use of recommended heart medications, and reduces hospital visits and other healthcare use.\n\nParticipants will be randomly assigned to one of the two groups. Those referred to the clinic will: 1) Meet with a cardiologist for an initial evaluation. 2) Be referred to other specialists (such as endocrinology, nephrology, or hepatology) based on their needs. 3) Receive ongoing, coordinated care from a team of specialists working together to improve their heart and metabolic health.",[294,30,122],"ASCVD",[294,296,297,122,30],"Cardiometabolic Clinic","Prevention","2026-02-23",{"date":300,"type":38},"2026-02-24",{"date":302,"type":24},"2026-06-02",{"date":304,"type":24},"2027-12-27",{"name":306,"class":45},"Duke University",{"id":308,"slug":309,"hasResults":12,"nctId":310,"briefTitle":311,"officialTitle":311,"acronym":4,"eligibilityCriteria":312,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":313,"targetDuration":4,"studyType":25,"phases":315,"briefSummary":316,"conditions":317,"keywords":319,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":324,"lastUpdatePostDateStruct":325,"startDateStruct":327,"completionDateStruct":329,"leadSponsor":331,"locationsCount":87},"100623739","prospective-exploratory-study-on-the-comprehensive-application-effectiveness-of-exercise-prescription-decision-support-tools-in-the-management-of-patients-with-four-highs-hypertension-hyperglycemia-hyperlipidemia-hyperuricemia-100623739","NCT07400549","Prospective Exploratory Study on the Comprehensive Application Effectiveness of Exercise Prescription Decision Support Tools in the Management of Patients With \"Four Highs\" (Hypertension, Hyperglycemia, Hyperlipidemia, Hyperuricemia)","Inclusion Criteria:\n\n1. Aged 18 years or older.\n2. Willing to participate in the study and able to provide written informed consent.\n3. Diagnosed with at least one of the following \"Four Highs\" conditions:\n\n   Hypertension: Diagnosed primary hypertension, defined as seated office SBP ≥ 140 mmHg and\u002For DBP ≥ 90 mmHg on at least three non-consecutive days, or currently taking antihypertensive medication. Blood pressure must be controlled while on four or more antihypertensive agents. Diabetes Mellitus: Diagnosed diabetes, defined as having typical symptoms plus random plasma glucose ≥ 11.1 mmol\u002FL, or fasting plasma glucose ≥ 7.0 mmol\u002FL, or 2-hour plasma glucose during OGTT\n\n   ≥ 11.1 mmol\u002FL, or HbA1c ≥ 6.5%, or currently taking glucose-lowering medication. HbA1c level must be between 6.5% and 13.0%. Hyperlipidemia: Diagnosed hyperlipidemia, defined as total cholesterol (TC) ≥ 6.22 mmol\u002FL, or LDL-C ≥ 4.14 mmol\u002FL, or HDL-C \\\u003C 1.04 mmol\u002F L, or triglycerides (TG) \\> 2.26 mmol\u002FL, or currently taking lipid-lowering medication. Hyperuricemia: Diagnosed hyperuricemia, defined as a fasting serum uric acid level \\> 420 μmol\u002FL (7 mg\u002FdL) in men and postmenopausal women, or \\> 360 μmol\u002FL (6 mg\u002FdL) in premenopausal women, on two non-consecutive days under a normal purine diet, or currently taking urate-lowering medication.\n4. Capable of using a smartphone.\n5. A local permanent resident who receives basic public health service management at the designated community health center\u002Fstation or township hospital.\n6. Has not engaged in regular moderate- to vigorous-intensity physical activity (defined as at least 30 minutes per session, on at least 3 days per week) in the past three months.\n\nExclusion Criteria:\n\nPatients meeting any of the following criteria will be excluded:\n\n1. History or acute episode of cardiovascular or cerebrovascular disease, including: angina pectoris, myocardial infarction, coronary revascularization surgery, stroke (ischemic or hemorrhagic, including transient ischemic attack), symptomatic peripheral arterial disease requiring surgery or diagnosed by vascular imaging, ventricular arrhythmia, uncontrolled atrial fibrillation, congestive heart failure (New York Heart Association Class III or IV), hypertrophic cardiomyopathy, history of aneurysm with diameter ≥ 5.5 cm or prior aneurysm surgery.\n2. Current malignant tumor or history of malignant tumor within the past five years.\n3. Contraindications to exercise, such as bone and joint diseases.\n4. Severe respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD), restricted lung volume (due to obesity, pregnancy, or spinal deformity), or cystic fibrosis.\n5. Neuromuscular and degenerative diseases, such as muscular dystrophy, poliomyelitis, and dementia.\n6. Severe mental illness, including schizophrenia, bipolar disorder, eating disorders, or depression (with hospitalization for the condition within the past 6 months).\n7. Movement and other neurological disorders, such as Huntington's disease, torsion dystonia, Parkinson's disease, and certain epileptic disorders.\n8. Severe comorbidities with a life expectancy of less than 24 months.\n9. Plans to relocate from the area within the next three months.\n10. Participation in other physical activity level intervention programs within the six months prior to the screening visit.\n11. Current participation in another randomized clinical trial.\n12. Any other condition that, in the investigator's judgment, may interfere with adherence to the trial protocol.",{"count":314,"type":24},100,[27],"This study conducted a six-month exploratory clinical trial to evaluate the impact of an exercise prescription mini-program, based on the \"Exercise Guidelines for the 'Four Highs'\", on the physical activity levels and related health indicators of patients with hypertension, hyperglycemia, hyperlipidemia, and hyperuricemia in primary healthcare settings in China.",[122,124,30,267,318],"Digital Intervention",[320,321,322,323],"Digitally-Enabled Health","Chronic Disease Prevention and Control","Sports prescription","Primary health care (PHC)","2026-02-09",{"date":326,"type":38},"2026-02-10",{"date":328,"type":38},"2025-06-01",{"date":330,"type":24},"2026-03-01",{"name":332,"class":333},"China National Center for Cardiovascular Diseases","OTHER_GOV",{"id":335,"slug":336,"hasResults":12,"nctId":337,"briefTitle":338,"officialTitle":339,"acronym":4,"eligibilityCriteria":340,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":260,"enrollmentInfo":341,"targetDuration":4,"studyType":25,"phases":343,"briefSummary":345,"conditions":346,"keywords":347,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":349,"lastUpdatePostDateStruct":350,"startDateStruct":352,"completionDateStruct":354,"leadSponsor":356,"locationsCount":87},"100610556","phase-1-a-study-to-evaluate-cor-1004-in-adult-volunteers-100610556","NCT07229118","A Study to Evaluate COR-1004 in Adult Volunteers.","A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered COR-1004","Inclusion Criteria:\n\n* Serum LDL-C ≥100 mg\u002FdL (≥2.6 mmol\u002FL) at Screening.\n* Female participants who are of childbearing potential must be willing to use two highly effective methods of contraception, one of which should be a barrier method.\n* Post-menopausal females must be post-menopausal for 12 months.\n* Male participants and their partners of child-bearing potential, or same-sex partners, must be willing to use two highly effective methods of contraception, one of which must be a barrier method (eg, condom) for 90 days after study drug administration.\n* Able to participate, and willing to give written informed consent and to comply with the study restrictions.\n\nExclusion Criteria:\n\n* Any active or chronic disease.\n* Active or history of serious mental illness or psychiatric disorder.\n* Clinically significant illness within seven days before study drug administration.\n* Having risk of atherosclerotic cardiovascular disease (ASCVD) ≥7.5% based on the ASCVD Risk Estimator Plus.\n* Having fasting triglyceride level ≥400 mg\u002FdL (≥4.52 mmol\u002FL).\n* Clinically significant abnormalities on physical examination, vital signs, or laboratory test results (except for serum LDL-C) during Screening or prior to admission to the study unit.\n* Participants with any risk factors or family history for QT or Fridericia-corrected QT interval (QTcF) prolongation or ECG abnormalities or any abnormality in the ECG.\n* Confirmed systolic blood pressure (SBP) \\>140 mmHg or diastolic blood pressure (DBP) \\>90 mmHg at Screening, Day -1, or pre-dose.\n* Mean resting pulse rate \\\u003C40 bpm or \\>90 bpm at Screening.\n* Abnormal renal function including serum creatinine greater than the upper limit of normal (ULN) or calculated creatinine clearance \\\u003C60 mL\u002Fmin (using the Cockcroft-Gault formula).\n* Alanine aminotransferase (ALT) and\u002For total bilirubin above the ULN. Aspartate aminotransferase (AST), alkaline phosphatase (ALP), or gamma glutamyl transferase (GGT) \\>2 × ULN. International normalized ratio (INR) above the upper bound of the normal reference range (as per the local laboratory reference range) at Screening.\n* Positive hepatitis B surface antigen, hepatitis B virus, hepatitis C virus, or human immunodeficiency virus infection.\n* Pregnant or lactating women, or males with female partners who are pregnant or lactating.\n* History of multiple drug allergies or history of allergic reaction to an oligonucleotide, N-acetylgalactosamine (GalNAc), or inclisiran.\n* Participation in an investigational drug or device study within 45 days or five half-lives (whichever time period is longer) or six months for biologic therapies prior to study drug administration.\n* Received small interfering ribonucleic acid (siRNA) as an investigational or approved product prior to study drug administration.\n* Use of any medications (prescription or over-the-counter) or herbal supplements within two weeks or five half-lives (whichever is longer) prior to study drug administration (six months for biologic therapies), with exception of acetaminophen\u002Fparacetamol up to 2 g per day up to 48 hours prior to dosing or medications for contraception. Other exceptions will only be made if the rationale is discussed and clearly documented between the Clinical Research Organization and Sponsor.\n* Received any medication, herbal supplements, or nutraceutical known to alter serum lipids within 30 days before Screening (eg, niacin).",{"count":342,"type":24},60,[344],"PHASE1","This research study is being done to see if a new, injectable drug called COR-1004 is safe for people to take. It will also help doctors find the right dose of the drug. The study will look at how different dose levels of COR-1004 affect the levels of LDL cholesterol (often called \"bad\" cholesterol) in the blood. The study will enroll otherwise healthy volunteers who have LDL cholesterol of 100 mg\u002Fdl or higher but are not currently taking any cholesterol-lowering medicines.\n\nThe main purpose of this study is to test a new drug, COR-1004. Researchers want to find out:\n\n* If the drug is safe and if people have any side effects.\n* The highest dose that can be given without causing serious side effects.\n* How the body processes the drug.\n* How the drug affects the amount of \"bad\" cholesterol in the blood.\n\nThis is an early-phase study. The information learned will help decide if COR-1004 should be tested in larger studies in the future.\n\nTo be in this study, you must:\n\n* Be generally healthy.\n* Have an LDL (\"bad\") cholesterol level of 100 mg\u002FdL or higher.\n* Not currently be taking any medications to lower your cholesterol.\n\nIf you decide to join the study, you will be placed into a group by chance, like flipping a coin. This is called \"randomization.\" In each group, most people (8 out of 10) will get a single injection of the study drug (COR-1004). The other people (2 out of 10) will get a placebo. A placebo looks just like the study drug but has no active medicine in it. Using a placebo helps researchers understand the true effects of the real drug.\n\nThis is a \"double-blind\" study, which means that neither you nor the study doctor will know if you are getting the study drug or the placebo.\n\nThe study will test different dose levels of COR-1004. It will start with a low dose and, only if it is proven to be safe, will a new group of participants be given a slightly higher dose. To be extra safe, the first two people in each new dose group will be watched for 24 hours before the other eight people in that group get their injection.\n\nAfter the injection, you will need to visit the study clinic several times over the next year for follow-up. These visits will include:\n\n* Answering questions about your health.\n* Physical exams.\n* Blood tests to check your safety and your cholesterol levels.\n\nA special group of experts, called a Safety Review Committee, will carefully watch over the study to protect all participants.\n\nYour active participation in the study, including follow-up visits, will last for about 12 months after you receive the single injection.\n\nBecause COR-1004 is a new drug, there may be risks that are not yet known. The study staff will explain all the known risks to you before you agree to participate. Known risks may include discomfort at the injection site, like redness, swelling, or pain. The study team will monitor you very closely for any side effects throughout the study.",[30],[30,348],"lipid-lowering therapy","2026-01-27",{"date":351,"type":38},"2026-01-28",{"date":353,"type":38},"2025-11-28",{"date":355,"type":24},"2027-11",{"name":357,"class":161},"Corsera Health",{"id":359,"slug":360,"hasResults":12,"nctId":361,"briefTitle":362,"officialTitle":363,"acronym":364,"eligibilityCriteria":365,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":366,"targetDuration":4,"studyType":25,"phases":367,"briefSummary":368,"conditions":369,"keywords":370,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":375,"lastUpdatePostDateStruct":376,"startDateStruct":378,"completionDateStruct":380,"leadSponsor":382,"locationsCount":87},"100618685","implementation-of-an-algorithm--and-multi-professional-team-supported-strategy-to-improve-lipid-management-of-patients-with-atherosclerotic-cardiovascular-disease-100618685","NCT07334834","Implementation of an Algorithm- and Multi-professional Team-supported Strategy to Improve Lipid Management of Patients With Atherosclerotic Cardiovascular Disease","Implementation of an Algorithm- and Multi-professional Team-supported Strategy to Improve Lipid Management of Patients With Atherosclerotic Cardiovascular Disease: OPTIMIZE ASCVD","OPTIMIZE ASCVD","Inclusion Criteria:\n\n* Provided informed consent\n* Age \\>18 years inclusive at screening\n* Documented atherosclerotic vascular disease including:\n\n  * Coronary artery disease (prior revascularization, myocardial infarction, imaging evidence of coronary atherosclerosis)\n  * Peripheral artery disease (prior revascularization, amputation, ankle: brachial index (ABI) ≤ 0.90, imaging evidence of extra-coronary atherosclerosis)\n  * Carotid artery disease (prior endarterectomy or stenting of the extracranial carotid artery or imaging evidence of carotid atherosclerosis)\n  * Imaging evidence of atherosclerotic vascular disease in a non-coronary vascular bed (e.g. aorta, mesenteric, renal)\n  * LDL-C \\>70mg\u002FdL\n\nExclusion Criteria:\n\n* Any reason that, in the opinion of the investigator, the patient would be unable to adhere to the protocol for the duration of the study (e.g. terminal diagnosis, metastatic cancer) or in whom participation might result in harm.\n* Planned active titration of current lipid-lowering therapy\n* Myocardial infarction or arterial revascularization within prior 30 days",{"count":314,"type":24},[27],"This is a randomized, controlled, collaborative, multicenter, pilot implementation science study evaluating the hypothesis that algorithm- and multi-professional team-supported lipid management reduces low density lipoprotein-cholesterol (LDL-C) compared with usual care in patients with atherosclerotic cardiovascular disease (ASCVD).",[30],[371,372,208,373,374],"Lipid Management","Atherosclerotic Cardiovascular Disease","Peripheral Artery Disease","Carotid Artery Disease","2026-01-22",{"date":377,"type":38},"2026-01-23",{"date":379,"type":38},"2025-12-10",{"date":381,"type":24},"2027-07",{"name":383,"class":45},"Colorado Prevention Center",{"id":385,"slug":386,"hasResults":12,"nctId":387,"briefTitle":388,"officialTitle":388,"acronym":4,"eligibilityCriteria":389,"healthyVolunteers":12,"sex":390,"minAge":391,"maxAge":392,"enrollmentInfo":393,"targetDuration":4,"studyType":25,"phases":395,"briefSummary":396,"conditions":397,"keywords":403,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":406,"lastUpdatePostDateStruct":407,"startDateStruct":409,"completionDateStruct":411,"leadSponsor":413,"locationsCount":87},"100590349","inspire-her-inspiring-the-heart-and-emotions-for-radical-health-100590349","NCT06966258","Inspire HER: Inspiring the Heart and Emotions for Radical Health","Inclusion Criteria:\n\n* Black women (self-report)\n* Adult ages 30-79 years\n* Stage 2 or greater Cardiovascular-Kidney-Metabolic Syndrome\n* English speaking\n* Lives in Metropolitan Birmingham, AL area.\n\nExclusion Criteria:\n\n\\- Healthcare provider-imposed physical activity limitations.","FEMALE","30 Years","79 Years",{"count":394,"type":24},90,[27],"Poor heart health puts Black women at risk for a shorter life with more illness than people of any other non-indigenous racial group. We will refine and conduct a randomized, wait-list controlled trial of Inspire HER (a heart health lifestyle intervention for Black women that provides health education, physical activity, and social resources). We will also compare Inspire HER and Black Impact (a heart health intervention for Black men) data to study how women and men respond differently to stress. This trial aligns with American Heart Association's pledge to address heart health equity through new interventions that consider the person and the circumstances with which they live.",[398,213,122,399,30,400,401,402],"Cardiovascular-kidney-metabolic Syndrome","Diabetes","Kidney Disease","Obesity","Smoking",[404,405],"Cardiovascular Risk","Lifestyle intervention","2025-12-19",{"date":408,"type":38},"2025-12-29",{"date":410,"type":38},"2025-11-15",{"date":412,"type":24},"2029-03-31",{"name":414,"class":45},"University of Alabama at Birmingham",{"id":416,"slug":417,"hasResults":12,"nctId":418,"briefTitle":419,"officialTitle":420,"acronym":4,"eligibilityCriteria":421,"healthyVolunteers":18,"sex":19,"minAge":422,"maxAge":423,"enrollmentInfo":424,"targetDuration":4,"studyType":25,"phases":426,"briefSummary":427,"conditions":428,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":429,"lastUpdatePostDateStruct":430,"startDateStruct":432,"completionDateStruct":433,"leadSponsor":435,"locationsCount":87},"100616988","phase-1-a-study-to-evaluate-the-pharmacokinetic-interaction-and-the-safety-of-ad-231a-and-ad-231b-and-ad-231c-100616988","NCT07312773","A Study to Evaluate the Pharmacokinetic Interaction and the Safety of AD-231A and AD-231B and AD-231C","A Two-arm, Open-label, Single-sequence, Multiple-dose Study to Evaluate the Pharmacokinetic Interaction and the Safety of AD-231A and AD-231B and AD-231C in Healthy Adult Volunteers","Inclusion Criteria:\n\n* Healthy adult volunteers aged ≥19 and \\\u003C65 years at the time of the screening visit\n* Body weight ≥50 kg (≥45 kg for females) and body mass index (BMI) between 18.0 kg\u002Fm² and 30.0 kg\u002Fm² at the time of the screening visit\n\nExclusion Criteria:\n\n* Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration\n* Other exclusions applied","19 Years","64 Years",{"count":425,"type":24},55,[344],"To evaluate the pharmacokinetic interactions of AD-231A, AD-231B, and AD-231C in healthy adult volunteers.",[122,30],"2025-12-17",{"date":431,"type":38},"2025-12-31",{"date":377,"type":24},{"date":434,"type":24},"2026-02-22",{"name":436,"class":161},"Addpharma Inc.",{"id":438,"slug":439,"hasResults":12,"nctId":440,"briefTitle":441,"officialTitle":442,"acronym":443,"eligibilityCriteria":444,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":445,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":446,"conditions":447,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":429,"lastUpdatePostDateStruct":449,"startDateStruct":450,"completionDateStruct":452,"leadSponsor":454,"locationsCount":87},"100616924","rapid-escalation-of-lipid-lowering-therapy-to-reduce-recurrent-cardiovascular-event-100616924","NCT07311941","Rapid Escalation of LipiD Lowering Therapy to Reduce RecUrrent Cardiovascular Event","Rapid Escalation of LipiD Lowering Therapy to Reduce RecUrrent Cardiovascular Event (REDUCE) : All Comers Study","REDUCE-Lipid","Inclusion Criteria:\n\n* Age \\>18\n* (Cohort 1) Diagnosis of acute coronary syndrome due to atherosclerotic coronary artery disease\n* (Cohort 2) Diagnosis of chronic coronary syndrome due to atherosclerotic coronary artery disease\n\nExclusion Criteria:\n\n* Inability to provide valid consent by the patient or his legal guardian\n* Diagnosis of ACS due to other causes than atherosclerotic coronary artery disease.\n* Psychiatric or severe neurological disorder, cirrhosis, or active malignancy leading to a life expectancy \\\u003C 6 months.",{"count":119,"type":24},"Hyperlipidaemia especially elevation of low-density lipoprotein cholesterol (LDL-C) is known to be the main contributor to the development of atherosclerotic cardiovascular disease (ASCVD).\n\nLowering LDL-C have been shown to reduce the risk of ASCVD2,3. Both the American Heart Association (AHA) and the European Society of Cardiology (ESC) advocated aggressive LDL-C target with statin being the first-line lipid-lowering therapy (LLT). However, a significant portion of patients did not attain their LDL-C goal in our locality. Statin no adherence, low uptake of adjuvant non-statin LLT, and therapeutic inertia are few potential causes for not achieving the LDL-C target. ESC recommends repeating blood test in 6-8 weeks after addition or alternation of LLT, but this recommendation was not routinely followed in current local practice due to resources constrain.\n\nThis registry therefore aims to investigate the strategy of frequent monitoring of LDL-C and titration of LLT in achieving LDL-C treatment target at a dedicated specialist clinic.",[30,448],"Cardio Vascular Disease",{"date":431,"type":38},{"date":451,"type":38},"2024-12-30",{"date":453,"type":24},"2031-06-30",{"name":455,"class":45},"Chinese University of Hong Kong",{"id":457,"slug":458,"hasResults":12,"nctId":459,"briefTitle":460,"officialTitle":461,"acronym":4,"eligibilityCriteria":462,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":463,"targetDuration":4,"studyType":25,"phases":465,"briefSummary":467,"conditions":468,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":469,"lastUpdatePostDateStruct":470,"startDateStruct":472,"completionDateStruct":474,"leadSponsor":476,"locationsCount":87},"100610619","phase-2-a-phase-ii-study-to-evaluate-the-efficacy-and-safety-of-hrs-1301-in-participants-with-dyslipidemia-100610619","NCT07229937","A Phase II Study To Evaluate the Efficacy And Safety Of HRS-1301 In Participants With Dyslipidemia","A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of HRS-1301 in Participants With Dyslipidemia","Inclusion Criteria:\n\n1. Male and female ≥ 18 years old, who is able and willing to provide a written informed consent\n2. BMI ≥ 18.0 kg\u002Fm2\n3. Clinically diagnosed with ASCVD and LDL-C ≥ 1.8 mmol\u002FL OR, if no history of ASCVD, has intermediate to high risk of developing ASCVD and LDL-C ≥ 2.6 mmol\u002FL\n4. Male and female subjects of childbearing potential and their partners must have no plans to donate sperm or become pregnant during the entire study period and for 2 weeks after the last dose, and agree to use contraceptive methods as specified in the protocol\n\nExclusion Criteria:\n\n1. TG \\> 5.6 mmol\u002FL\n2. Diagnosed with homozygous familial hypercholesterolemia (HoFH)\n3. Acute ischemic ASCVD events within 12 months before screening, or during the screening and run-in phase\n4. Heart failure with New York Heart Association (NYHA) Class III-IV\n5. Malignant tumors within 5 years\n6. Received or is regularly receiving LDL or plasma apheresis within 12 months before screening\n7. History or presence of severe gastrointestinal, hepatic, or renal diseases, or other known diseases that may interfere with drug absorption, distribution, metabolism, or excretion\n8. Uncontrolled diabetes mellitus and\u002For hypertension\n9. Has undergone transplantation of any vital organ, such as lung, liver, heart, bone marrow, or kidney",{"count":464,"type":24},189,[466],"PHASE2","The purpose of the study is to explore the reasonable dosage of HRS-1301 in participants with dyslipidemia. The efficacy and safety of HRS-1301 will be evaluated after 12-weeks treatment.",[30],"2025-12-11",{"date":471,"type":38},"2025-12-12",{"date":473,"type":38},"2025-11-25",{"date":475,"type":24},"2026-08",{"name":477,"class":161},"Shandong Suncadia Medicine Co., Ltd.",{"id":479,"slug":480,"hasResults":12,"nctId":481,"briefTitle":482,"officialTitle":482,"acronym":483,"eligibilityCriteria":484,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":485,"enrollmentInfo":486,"targetDuration":4,"studyType":25,"phases":488,"briefSummary":489,"conditions":490,"keywords":494,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":379,"lastUpdatePostDateStruct":500,"startDateStruct":502,"completionDateStruct":504,"leadSponsor":506,"locationsCount":4},"100613970","smart-family-doctor-assisted-comprehensive-management-of-secondary-prevention-among-post-revascularization-patients-100613970","NCT07273513","\"Smart Family Doctor\" Assisted Comprehensive Management of Secondary Prevention Among Post Revascularization Patients","SMART II","Inclusion Criteria:\n\n* Age 18-80 years.\n* Underwent CABG or PCI more than 3 months prior and have concurrent hypertension, diabetes, and dyslipidemia.\n* At least one of the following criteria is meet:\n* Systolic blood pressure no less than 130 mmHg or diastolic blood pressure no less than 80 mmHg\n* HbA1c no less than 7%\n* LDL-C no less than 1.4 mmol\u002FL\n* Signed informed consent.\n\nExclusion Criteria:\n\n* History of heart failure or severe arrhythmias.\n* Presence of other severe underlying conditions such as cancer or liver and kidney insufficiency.\n* Pregnancy, lactation, or plans for pregnancy within the next year.\n* Cognitive, communication impairments, or limitations in daily activities.\n* Unable to use smartphone.","80 Years",{"count":487,"type":24},951,[27],"This study aims to evaluate the effect of an AI-assisted \"Smart family doctor\" digital health management tool on improving the control rates of hypertension, diabetes, and dyslipidemia in post-revascularization patients. A randomized controlled trial design will be used, involving approximately 10-20 hospitals and 951 participants. Eligible participants are adults aged between 18 and 80 years, post-CABG or post-PCI patients with hypertension, diabetes, and dyslipidemia.",[122,491,30,492,493],"Diabete Mellitus","Post PCI","Post CABG",[495,496,497,498,499],"smartphone","AI-assisted","Revascularization management","metabolic management","Smart family doctor",{"date":501,"type":38},"2025-12-18",{"date":503,"type":24},"2026-01-15",{"date":505,"type":24},"2027-01-15",{"name":332,"class":333},{"id":508,"slug":509,"hasResults":12,"nctId":510,"briefTitle":511,"officialTitle":511,"acronym":512,"eligibilityCriteria":513,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":514,"targetDuration":4,"studyType":25,"phases":516,"briefSummary":517,"conditions":518,"keywords":520,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":522,"lastUpdatePostDateStruct":523,"startDateStruct":525,"completionDateStruct":527,"leadSponsor":529,"locationsCount":87},"100563395","smart-family-doctor-assisted-comprehensive-management-of-secondary-prevention-among-post-coronary-artery-bypass-graft-patients-or-post-percutaneous-coronary-intervention-patients-100563395","NCT06615609","\"Smart Family Doctor\" Assisted Comprehensive Management of Secondary Prevention Among Post Coronary Artery Bypass Graft Patients or Post Percutaneous Coronary Intervention Patients","SMART","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* History of CABG surgery or PCI with history of hypertension, diabetes, and dyslipidemia.\n* At least one of the following criteria is meet:\n* Systolic blood pressure no less than 130 mmHg or diastolic blood pressure no less than 80 mmHg\n* HbA1c no less than 7%\n* LDL-C no less than 1.4 mmol\u002FL\n* Use of a smartphone.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* History of heart failure or severe arrhythmias.\n* Presence of other severe underlying conditions such as cancer or liver and kidney insufficiency.\n* Pregnancy, lactation, or plans for pregnancy within the next year.\n* Cognitive, communication impairments, or limitations in daily activities.",{"count":515,"type":24},536,[27],"This study aims to evaluate the effect of an AI-assisted \"Smart family doctor\" digital health management tool on improving the control rates of hypertension, diabetes, and dyslipidemia in post-CABG (coronary artery bypass grafting) patients or post-PCI (percutaneous coronary intervention) patients. A randomized controlled trial design will be used, involving approximately 5-10 hospitals and 536 participants. Eligible participants are adults aged 18 or older, post-CABG or post-PCI patients with hypertension, diabetes, and dyslipidemia.",[519,122,266,30,492],"Post Coronary Artery Bypass Grafting",[495,496,521,498,499],"CABG management","2025-12-02",{"date":524,"type":38},"2025-12-08",{"date":526,"type":38},"2025-09-24",{"date":528,"type":24},"2026-11-15",{"name":332,"class":333},{"id":531,"slug":532,"hasResults":12,"nctId":533,"briefTitle":534,"officialTitle":534,"acronym":4,"eligibilityCriteria":535,"healthyVolunteers":12,"sex":19,"minAge":536,"maxAge":21,"enrollmentInfo":537,"targetDuration":4,"studyType":25,"phases":539,"briefSummary":540,"conditions":541,"keywords":546,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":552,"lastUpdatePostDateStruct":553,"startDateStruct":555,"completionDateStruct":557,"leadSponsor":559,"locationsCount":87},"100573937","wearable-technology-data-driven-digital-health-coaching-activation--a-mixed-methods-study-100573937","NCT06752772","WeArable teChnology daTa driVen digitAl healTh cOachINg (ACTIVATION)- A Mixed-methods Study","Inclusion Criteria:\n\n* 21-75 years old\n* Patients who are at risk of any of the following:\n\n  1. Elevated blood pressure\n  2. Overweight (BMI\\>=23kg\u002Fm2)\n  3. Pre-diabetes, OR\n* Patients who have one or more of the following (HOLD) conditions:\n\n  1. Hypertension\n  2. Obesity (BMI\\>=27.5kg\u002Fm2)\n  3. HyperLipidemia\n  4. Type 2 Diabetes Mellitus\n* Patients who own a smartphone\n* Patients who are willing to wear a smartwatch during the intervention period.\n\nExclusion Criteria:\n\n* Patients who have a medical condition that prevented participation in physical activity\n* Patients who have current diagnosis or history of eating disorder, depression\n* Patients who are currently pregnant or planning to become pregnant in the next 6 months\n* Patients who are currently participating in a weight loss programme (commercial, medically supervised, or research study)\n* Patients who are on weight loss medications (over-the-counter or prescription)\n* Patients who are not mentally-, physically- or technologically-capable\n* Patients who is unable to provide informed consent.","21 Years",{"count":538,"type":24},1700,[27],"Public health priorities have shifted towards disease prevention, emphasising health promotion and lifestyle interventions to reduce disease burden. Despite global efforts, the prevalence of chronic diseases remains high, with lifestyle factors such as alcohol consumption, diet, smoking, obesity, and sedentary behaviour playing significant roles. In Singapore, suboptimal lifestyle behaviours are common, contributing to a high incidence of chronic conditions. Metabolic syndrome (MetS), linked to obesity, poses a growing societal burden due to its association with cardiovascular risks. Disparities exist in the delivery of lifestyle interventions among healthcare providers (HCPs), with many patients receiving inadequate guidance. Digital health coaching, incorporating wearable technology, offers promising solutions to bridge these gaps, providing personalised, real-time support and feedback to improve lifestyle behaviours and prevent disease progression. Challenges such as time constraints, lack of feedback, and limited support can be addressed through remote monitoring and tailored interventions, making scalable population-level interventions feasible.",[542,122,543,544,30,545],"Elevated Blood Pressure","Overweight\u002FObesity","Type 2 Diabetes Mellitus (T2DM)","Prediabetes",[547,548,549,550,551],"Digital Health Intervention","Health Coaching","Personalisation","Nudging","Wearables","2025-09-29",{"date":554,"type":38},"2025-10-02",{"date":556,"type":38},"2024-08-06",{"date":558,"type":24},"2026-02",{"name":560,"class":45},"Alexandra Hospital",{"id":562,"slug":563,"hasResults":12,"nctId":564,"briefTitle":565,"officialTitle":566,"acronym":4,"eligibilityCriteria":567,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":568,"enrollmentInfo":569,"targetDuration":4,"studyType":25,"phases":571,"briefSummary":572,"conditions":573,"keywords":575,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":579,"lastUpdatePostDateStruct":580,"startDateStruct":582,"completionDateStruct":584,"leadSponsor":586,"locationsCount":87},"100608165","2-hoba-supplementation-in-people-with-elevated-lipoproteina-100608165","NCT07198009","2-HOBA Supplementation in People With Elevated Lipoprotein(a)","Modulation of Bioactive Lipids in Lipid Disorders: a Pilot Study of 2-HOBA Supplementation in Individuals With Elevated Lipoprotein(a)","Inclusion Criteria:\n\n* Males and females aged 18-69 years.\n* Elevated Lp(a) levels ≥ 90 mg\u002FdL.\n* Able to provide informed consent and adhere to study schedules.\n* Willing to follow a physician-recommended diet during the study.\n\nExclusion Criteria:\n\n* Pregnant, planning pregnancy during the study period, or currently breastfeeding.\n* Individuals with established cardiovascular disease\n* Planning major changes in diet or exercise routines.\n* Experienced \\>20% weight change in the past 3 months.\n* Diagnosed with malabsorption syndrome or chronic diarrhea.\n* Abnormal liver, kidney, or thyroid function.\n* Drug or alcohol abuse within the past 6 months, or significant mental\u002Fpsychological impairment.\n* Have known bleeding disorders (e.g., hemophilia).\n* Planned surgery during the study period.\n* Donated blood within the last 2 weeks or planning to donate during the study.\n* Require regular blood transfusions.","69 Years",{"count":570,"type":24},10,[27],"The goal of this clinical trial is to learn if a natural supplement called 2-hydroxybenzylamine (2-HOBA) can reduce harmful oxidized lipids and improve the function of lipoprotein(a) in adults with high lipoprotein(a) levels.\n\nThe main questions it aims to answer are:\n\nDoes 2-HOBA lower oxidized phospholipids on lipoprotein(a)? Does 2-HOBA reduce markers of inflammation and blood clotting in the blood?\n\nParticipants will:\n\nTake 2-HOBA capsules (400 mg, three times daily with meals) for 6 weeks Provide blood and urine samples at the beginning, middle, and end of the study Have lab tests to measure changes in lipids, inflammation, and clotting markers",[30,574],"Elevated Lp(a)",[576,577,578],"Oxidized Phospholipids","lp(a)","2HOBA","2025-09-25",{"date":581,"type":38},"2025-09-30",{"date":583,"type":24},"2025-11-01",{"date":585,"type":24},"2026-11",{"name":587,"class":45},"The Miriam Hospital",{"id":589,"slug":590,"hasResults":12,"nctId":591,"briefTitle":592,"officialTitle":592,"acronym":4,"eligibilityCriteria":593,"healthyVolunteers":12,"sex":19,"minAge":260,"maxAge":4,"enrollmentInfo":594,"targetDuration":596,"studyType":57,"phases":4,"briefSummary":597,"conditions":598,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":604,"lastUpdatePostDateStruct":605,"startDateStruct":607,"completionDateStruct":609,"leadSponsor":611,"locationsCount":87},"100606808","assessment-and-management-of-multiple-drug-use-in-elderly-chronic-disease-patients-100606808","NCT07180368","Assessment and Management of Multiple Drug Use in Elderly Chronic Disease Patients","Inclusion Criteria:\n\n* Patients aged 65 years or older with at least one chronic disease\n\nExclusion Criteria:\n\n* Patients without chronic diseases\n* Patients refused to participate in the study\n* Patients with unstable vital signs",{"count":595,"type":24},2000,"1 Day","The purpose of this observational study is to understand the impact of polypharmacy on the prognosis of elderly patients with chronic diseases. The main research question it aims to address is:\n\nDoes polypharmacy affect the prognosis of elderly patients with chronic diseases? Elderly patients with chronic diseases will be asked to complete online survey questions regarding their disease prognosis over a 2-year period.",[208,491,599,122,600,30,601,602,603],"Chronic Kidney Disease","Heart Failure","Obesity &Amp; Overweight","Chronic Obstructive Pulmonary Disease (COPD)","Stroke","2025-09-11",{"date":606,"type":38},"2025-09-18",{"date":608,"type":38},"2024-10-01",{"date":610,"type":24},"2027-09-30",{"name":612,"class":45},"Xijing Hospital",{"id":614,"slug":615,"hasResults":12,"nctId":616,"briefTitle":617,"officialTitle":617,"acronym":618,"eligibilityCriteria":619,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":620,"targetDuration":4,"studyType":25,"phases":622,"briefSummary":623,"conditions":624,"keywords":628,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":630,"lastUpdatePostDateStruct":631,"startDateStruct":633,"completionDateStruct":635,"leadSponsor":637,"locationsCount":87},"100602142","targeting-metabolic-syndrome-from-the-emergency-department-through-mixed-methods-pilot-trial-100602142","NCT07119658","Targeting Metabolic Syndrome From the Emergency Department Through Mixed-Methods: Pilot Trial","METS","Inclusion Criteria:\n\n* Ambulatory adults (18 years of age) presenting to the emergency department setting\n* BMI 30 kg\u002Fm2\n* Prior diagnosis of at least one additional comorbid component of metabolic syndrome: hypertension, hyperglycemia, dyslipidemia\n* Clinical plan for discharge\n\nExclusion Criteria:\n\n* Age \\\u003C18 years\n* Pregnant patients\n* Unable to safely ambulate (including patient or family perception of inability to safely ambulate)\n* Lack of access to smart phone\n* Unable or unwilling to wear Fitbit accelerometer device\n* Unable to obtain informed consent",{"count":621,"type":24},20,[27],"The objective of this study is to pilot a multifaceted, optimized intervention for metabolic syndrome (MetS) in emergency department patients to establish feasibility. Participants (n=20) will be randomized to intervention or control (usual care). The composite intervention will include an educational video outlining the adverse effects of MetS and the benefit of walking, a written exercise prescription with a defined goal of walking 150 minutes per week, a Fitbit accelerometer device, resources for healthy eating practices, periodic text message reminders, and an urgent referral to primary care and our health system's Healthy Me clinic for follow-up visit. Investigators hypothesize that this approach will change patient understanding and motivation to increase physical activity and healthy eating habits.",[122,124,625,626,601,399,30,627],"Dyslipidemia","Metabolic Syndrome","Emergency Medicine",[626,629],"Emergency Department","2025-08-05",{"date":632,"type":38},"2025-08-13",{"date":634,"type":38},"2025-07-08",{"date":636,"type":24},"2026-07",{"name":638,"class":45},"Indiana University",{"id":640,"slug":641,"hasResults":12,"nctId":642,"briefTitle":643,"officialTitle":644,"acronym":4,"eligibilityCriteria":645,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":260,"enrollmentInfo":646,"targetDuration":4,"studyType":25,"phases":648,"briefSummary":649,"conditions":650,"keywords":651,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":654,"lastUpdatePostDateStruct":655,"startDateStruct":657,"completionDateStruct":659,"leadSponsor":661,"locationsCount":87},"100589045","intervention-study-on-digital-health-management-100589045","NCT06949306","Intervention Study on Digital Health Management","Intervention of a Digital Health Management Program in Patients With Cardiometabolic Disorders: a Real-world Study","Inclusion Criteria:1. Age 18-65 years old; 2. Meet one of the following three conditions:\n\n1. Diastolic hypertension (systolic blood pressure \\\u003C 140 MMHG and diastolic blood pressure ≥90mmHg)\n2. Glycosylated hemoglobin (6.0-6.5)\n3. Obesity (BMI≥28kg\u002Fm²)\n4. Mild hyperlipemia: total cholesterol (TC) ≥5.2 mmol\u002FL and \\\u003C 6.2 mmol\u002FL, or low-density lipoprotein cholesterol (LDL-C) ≥3.4 mmol\u002FL and \\\u003C 4.1 mmol\u002FL 3. Antihypertensive or lipid-lowering medications have not been started 4. Use a smartphone and volunteer\n\nExclusion Criteria:\n\n1. Complicated with chronic liver and kidney disease, coronary heart disease, heart failure and severe valvular disease\n2. Previous cardiovascular and cerebrovascular events\n3. Diastolic blood pressure ≥99mmHg\n4. Glycated hemoglobin ≥6.5\n5. Other life expectancy such as cancer is less than 5 years\n6. Participate in other clinical trials",{"count":647,"type":24},300,[27],"The aim of this study is to construct a digital precision intervention system for cardiometabolism disorders based on the characteristics of the Chinese population, focusing on the core components of metabolic syndrome such as hypertension, hyperglycemia, and obesity. Through dynamic monitoring of wearable devices, the individualized risk factors (including genetic predisposition, lifestyle, and psychological factors) of metabolic disorders were systematically analyzed, and dynamic intervention strategies were formulated accordingly. The closed-loop management of \"monitor-feedback-optimization\" based on the digital platform will provide patients with one-stop metabolic risk assessment and panoramic health management plan, realizing a paradigm shift from \"generalized intervention\" to \"precise regulation\". By reducing the abnormal fluctuations of key metabolic indicators such as blood pressure, blood glucose, and blood lipids, the risk of cardiovascular events will eventually be reduced, the long-term quality of life of patients will be improved, and a practical path of \"digital therapy\" can be promoted for the prevention and control of chronic diseases in China",[122,30],[652,653],"Cardiometabolic abnormalities","Digital Interventions","2025-04-21",{"date":656,"type":38},"2025-04-29",{"date":658,"type":24},"2025-07-01",{"date":660,"type":24},"2030-12-31",{"name":110,"class":45},{"id":663,"slug":664,"hasResults":12,"nctId":665,"briefTitle":666,"officialTitle":667,"acronym":668,"eligibilityCriteria":669,"healthyVolunteers":12,"sex":19,"minAge":670,"maxAge":21,"enrollmentInfo":671,"targetDuration":4,"studyType":25,"phases":673,"briefSummary":674,"conditions":675,"keywords":680,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":684,"lastUpdatePostDateStruct":685,"startDateStruct":687,"completionDateStruct":689,"leadSponsor":691,"locationsCount":87},"100585834","preventative-screening-and-health-coaching-in-a-food-insecure-population-100585834","NCT06907524","Preventative Screening and Health Coaching in a Food Insecure Population","Community-Based Preventative Cardiometabolic Screening and Health Coaching- A Prospective Study","HEALTHCOACH","Inclusion:\n\nPatient is a participant at a CHI sponsored, community screening event Patient provides informed consent and willingness to participate for the duration of the study English or Spanish speaking Age 40-75 years old At least 1 cardiometabolic risk factor at suboptimal level\n\nDefined as one or more of the following at initial screening:\n\nBlood Pressure (BP):\n\nSystolic BP greater than 130mmHg and\u002For diastolic BP greater than 80mmHg. Obesity: body mass index (BMI) greater than 30 〖kg\u002Fm〗\\^2\n\nDyslipidemia:\n\nTotal cholesterol greater than 200 mg\u002FdL Triglycerides greater than 150 mg\u002FdL Low density lipoprotein (LDL) greater than 130 mg\u002FdL High density lipoprotein (HDL) less than 40 mg\u002FdL in men or less than 50 mg\u002FdL in women Hemoglobin A1c greater than or equal to 5.7% 10-year ASCVD score greater than 5% Access to a telehealth compatible device\n\nExclusion:\n\nAdults unable to provide informed consent or unwilling to participate for study duration Speaks language other than English or Spanish Younger than 40 years old or older than 75 years old All cardiometabolic risk factors at optimal levels No telehealth compatible device Pregnant patients","40 Years",{"count":672,"type":24},200,[27],"The goal of this longitudinal study is to investigate the role of virtual health coaching on mitigation of cardiometabolic disease risk in an underserved, food insecure population. The main questions it aims to answer are:\n\n* Does longitudinal, individualized health coaching directed at lifestyle modification reduce patient 10-year risk of heart attack or stroke?\n* Does longitudinal, individualized health coaching directed at lifestyle modification reduce rates of hypertension, hyperlipidemia, and diabetes?\n* Does longitudinal, individualized health coaching directed at lifestyle modification improve accessibility to healthcare?\n\nResearchers will investigate the effects of regularly scheduled health coaching sessions on composite cardiometabolic risk profile as well as individual modifiable cardiovascular risk factors.\n\nParticipants will:\n\n* Participate in in-person cardiovascular screening, occuring at the time of enrollment, months 3 and 6.\n* Engage in virtual health coaching sessions to talk about diet, exercise, weight loss, blood pressure and diabetes control, and accessibility to healthcare\n* Keep a log of their blood pressure",[178,676,677,678,122,30,399,679,548],"Cardiometabolic Diseases","Cardiovascular Risk Factor","Cardiovascular Risk Score","Lifestyle Modification",[178,681,122,30,399,679,548,678,682,677,683],"Cardiometabolic Disease Screening","Atherosclerotic Cardiovascular Disease Risk Score","Cardiometabolic Disease","2025-03-26",{"date":686,"type":38},"2025-04-02",{"date":688,"type":24},"2025-04-01",{"date":690,"type":24},"2027-07-01",{"name":692,"class":45},"Rush University Medical Center"]